CBIO Key Statistics, Chart & Performance
The current stock price of CBIO is 9.54 USD. In the past month the price decreased by -14.13%.
CBIO Technical Analysis
CBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CBIO. The financial health of CBIO is average, but there are quite some concerns on its profitability.
CBIO Financial Highlights
Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -58. The EPS increased by 34.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| Debt/Equity | 0 |
CBIO Forecast & Estimates
13 analysts have analysed CBIO and the average price target is 27.03 USD. This implies a price increase of 183.33% is expected in the next year compared to the current price of 9.54.
CBIO Ownership
CBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.54 | 398.827B | ||
| AMGN | AMGEN INC | 15.03 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.04 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.87 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.12 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.44 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.23 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CBIO
Company Profile
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Company Info
CRESCENT BIOPHARMA INC
300 Fifth Avenue
Waltham MASSACHUSETTS 94080 US
CEO: Nassim Usman
Employees: 4
Phone: 16174305595
CRESCENT BIOPHARMA INC / CBIO FAQ
Can you describe the business of CRESCENT BIOPHARMA INC?
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
What is the current price of CBIO stock?
The current stock price of CBIO is 9.54 USD. The price decreased by -2.85% in the last trading session.
What is the dividend status of CRESCENT BIOPHARMA INC?
CBIO does not pay a dividend.
How is the ChartMill rating for CRESCENT BIOPHARMA INC?
CBIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does CRESCENT BIOPHARMA INC belong to?
CRESCENT BIOPHARMA INC (CBIO) operates in the Health Care sector and the Biotechnology industry.
What is CRESCENT BIOPHARMA INC worth?
CRESCENT BIOPHARMA INC (CBIO) has a market capitalization of 132.51M USD. This makes CBIO a Micro Cap stock.
What is the outstanding short interest for CRESCENT BIOPHARMA INC?
The outstanding short interest for CRESCENT BIOPHARMA INC (CBIO) is 7.64% of its float.